Epithelial cancers (carcinomas) comprise the top four causes of cancer-related deaths in the United States. While overall survival has been steadily improving, therapyresistant disease continues to present a major therapeutic challenge. Carcinomas often exploit the normal developmental program, epithelial-to-mesenchymal transition (EMT), to gain a mesenchymal phenotype associated with increased invasiveness and resistance to apoptosis. We have previously shown that an isoxazole-based small molecule, ML327, partially reverses TGF-β-induced EMT in an immortalized mouse mammary epithelial cell line. Herein, we demonstrate that ML327 reverses much of the EMT gene expression program in cultured carcinoma cell lines. The reversal of EMT sensitizes these cancer cells to the apoptosis-inducing ligand TRAIL. This sensitization is independent of E-cadherin expression and rather relies on the downregulation of a major anti-apoptotic protein, cFLIP S . Loss of cFLIP S is sufficient to overcome resistance to TRAIL and exogenous overexpression of cFLIP S restores resistance to TRAIL-induced apoptosis despite EMT reversal with ML327. In summary, we have utilized an isoxazolebased small molecule that partially reverses EMT in carcinoma cells to demonstrate that cFLIP S critically regulates the apoptosis resistance phenotype associated with EMT.
INTRODUCTION
Epithelial cancers (carcinomas) comprise the top four causes of cancer related deaths in the United States [1] . Overall survival for these malignancies has been steadily improving over the past several decades largely due to improved screening along with aggressive medical and surgical intervention. Despite these improvements, a major therapeutic challenge persists because cancer progression is usually associated with treatment resistance.
Cytotoxic chemotherapy induces apoptosis in susceptible, rapidly proliferating, cancer cells. Certain populations of cancer cells, however, obtain a stem-cell-like phenotype, divide slowly, resist apoptosis, and are thought to drive progression and recurrence despite aggressive medical therapy [2] .
Epithelial-to-mesenchymal transition (EMT) is a major cellular reprogramming of carcinomas that not only results in a mesenchymal phenotype, characterized by repression of E-cadherin expression and increased cancer Research Paper cell invasiveness, but also results in a chemotherapeuticresistant state [3] . Cells that have undergone EMT also acquire a cancer stem cell-like phenotype [4] . It has been proposed that these cancer stem cells evade apoptosis and ultimately lead to disease progression or recurrence [2, 5] . The potential to reverse EMT and re-sensitize cancer cells to apoptosis-inducing agents represents a novel strategy for the treatment of carcinomas.
Therapeutic application of the tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL, also known as APO2L or TNFSF10), a death receptor ligand, is especially appealing as it selectively induces apoptosis in cancer cells both in vitro and in vivo with minimal toxicity toward non-cancerous cells [6, 7] . While TRAIL and other death receptor agonists have been found safe and well tolerated in phase 1 and phase 2 clinical trials, these agents have not demonstrated any clinically significant antitumor effect when compared to standard therapy alone [8] . This failure to progress in clinical trials is likely due to pre-existing resistance to TRAIL in some cancer cells, and the rapid acquisition of resistance in others; however, the exact mechanism of this resistance is inadequately understood.
Anti-apoptotic proteins have been implicated in TRAIL resistance as these are often overexpressed in cancers and promote tumor progression and treatment failure [9, 10] . One such protein, the cellular FLICE-like inhibitory protein (cFLIP, also known as CASP8 and FADD-like apoptosis regulator, or CFLAR), is a potent anti-apoptotic protein known to negatively regulate TRAILinduced apoptosis. cFLIP is expressed primarily as two dominant splice variants, cFLIP Long (cFLIP L ) and cFLIP Short (cFLIP S ) [10] . While cFLIP L has been shown to be pro-apoptotic at physiologic levels, and not anti-apoptotic as previously thought [11] [12] [13] , cFLIP S is clearly an antiapoptotic protein. Structurally homologous to caspase 8, cFLIP S lacks inherent caspase catalytic activity and prevents release of active caspase 8 from the death-inducing signaling complex (DISC). Thus, cFLIP S triggers cells to activate pro-survival signaling pathways in response to TRAIL rather than pro-apoptotic pathways [14] .
EMT also plays a major role in TRAIL resistance [15] . Indeed, it has been proposed that E-cadherin expression is necessary for apoptosis induction by TRAIL [16] . We previously characterized and reported our discovery of an isoxazole-based small molecule probe, ML327, that de-represses E-cadherin expression and partially reverses the EMT phenotype [17, 18] . In the current report, we demonstrate that EMT reversal by ML327 is accompanied by an augmented response to the TRAIL ligand in carcinoma cells that is independent of E-cadherin expression. EMT reversal with ML327 resulted in a consistent downregulation of cFLIP S expression across a variety of cancer cell lines and our data support this downregulation of cFLIP S as the mechanism by which ML327 sensitizes carcinomas to TRAIL-induced apoptosis.
RESULTS

ML327 partially reverses EMT in carcinoma cells
Our previous work demonstrated a partial reversal of TGF-β-induced EMT with ML327 at a 10 μM concentration in an immortalized mouse mammary epithelial cell line as well as upregulation of E-cadherin in multiple cell lines [17] . We proceeded to test whether ML327 broadly regulates markers of EMT in several carcinoma cell lines independently of TGF-β treatment and therefore performed RNA sequencing (RNAseq) on HCT-116, SW620, and A549 cancer cell lines treated with 10 μM ML327 (or vehicle control) for 24 hours (Supplementary Tables 1-3) . Sequencing data demonstrated similar gene expression changes across all 3 cancer cell lines with 730 commonly upregulated genes and 37 commonly downregulated genes (Supplementary Table 4 ). EMT and stem cell markers that are typically upregulated during EMT were downregulated after ML327 treatment ( Figure 1A ). Core expression analysis of the RNAseq data using Ingenuity Pathway Analysis (IPA) implicated "Regulation of the Epithelialto-Mesenchymal Transition Pathway" as one of the top organismal growth and development pathways in all 3 cancer cell lines ( Figure 1B, Supplementary Figure 1A) . We further assessed the RNAseq findings using gene set enrichment analysis (GSEA) and found positive enrichment of previously published EMT reversal signatures [19] [20] [21] as well as Gene Ontology (GO version 5.2) adherens junction functioning signatures [22, 23] (Figure 1C, Supplementary  Figure 1B) . Taken together, these data demonstrate that ML327 treatment partially reverses EMT in carcinoma cells.
EMT reversal sensitizes carcinoma cells to TRAIL-induced apoptosis
EMT is associated with resistance to therapyinduced apoptosis. As such, we tested whether partial EMT reversal with ML327 treatment would sensitize cancer cells to the apoptosis-inducing ligand, TRAIL. Three carcinoma cell lines were pre-treated with 10 μM ML327 for 24 hours and then TRAIL for 4 hours. ML327 pre-treatment alone did not result in poly ADP-ribose polymerase (PARP) cleavage. TRAIL treatment alone (after vehicle pre-treatment) resulted in low to moderate PARP cleavage, but the addition of TRAIL after ML327 pre-treatment resulted in a marked increase in PARP cleavage by 4 hours after TRAIL addition (Figure 2A , Supplementary Figure 2A) . ML327 pre-treatment followed by TRAIL also increased Annexin V binding to phosphatidylserine (PS) residues by 2 hours and persisted at 12 hours after TRAIL treatment (p < 0.0001) (Supplementary Figure 2B) . Caspase 8 cleavage was also increased by 4 hours after TRAIL addition www.impactjournals.com/oncotarget (Supplementary Figure 2C) . At later time points, too few viable cells remained to perform western blot analysis in the ML327+TRAIL treated cells (data not shown). We validated these findings with flow cytometric cell cycle analysis and luminescence-based caspase 3/7 activity assays under the same treatment conditions. Cell cycle analysis demonstrated an increased proportion of SW620 (p < 0.01) and HCT-116 (p < 0.01) cells in the Sub G 0 phase with ML327 pre-treatment followed by TRAIL for 4 hours ( Figure 2B ). Caspase 3/7 activity was also increased with ML327 pre-treatment followed by TRAIL for 4 hours in SW620 (p < 0.0001) and HCT-116 (p = 0.0007) cells ( Figure 2C ). To determine whether ML327 sensitized a non-transformed cell line to TRAIL-induced apoptosis, we examined PARP cleavage and caspase 3/7 activity in immortalized, but not transformed, young-adult mouse colon epithelial cells (YAMC) [24] using similar treatment conditions as above. Interestingly, there was no PARP cleavage with TRAIL alone or in combination with ML327 (Supplementary Figure 2D) and there was no difference in caspase 3/7 activity with ML327 pretreatment (as compared to vehicle pre-treatment) followed by TRAIL (Supplementary Figure 2E) . Taken together, these data suggest that partial EMT reversal with ML327 sensitizes carcinoma cells to TRAIL-induced apoptosis while sparing non-cancerous cells.
TRAIL sensitization following EMT reversal is independent of E-Cadherin expression
A hallmark of EMT is loss of the adherens junction protein E-cadherin via transcriptional repression. E-cadherin has been shown to couple death receptors to the cytoskeleton and potentiate apoptotic signaling upon death ligand binding [16] . To test whether E-cadherin expression is necessary for TRAIL sensitization, we first performed small interfering RNA (siRNA) knockdown of E-cadherin in SW620 cells, in which E-cadherin is de-repressed after ML327 treatment, and HCT-116 cells, which constitutively express E-cadherin. In both cell lines, E-cadherin knockdown did not blunt enhanced PARP cleavage with ML327 pre-treatment followed by TRAIL ( Figure 3A and 3B) .
We next tested the effect of ML327 on TRAIL sensitization in RKO colon cancer cells in which ML327 is unable to de-repress E-cadherin expression due to promoter hypermethylation [25] . Despite the absence of E-cadherin expression, ML327 pre-treatment followed by TRAIL resulted in increased PARP cleavage ( Figure 3C ), increased caspase 3/7 activity (p = 0.0095) (Supplementary Figure 3A) , increased cell percentage in the Sub G 0 phase on cell cycle analysis (p < 0.001) (Supplementary Figure 3B) , and increased Annexin V binding to PS residues (p < 0.0001) (Supplementary Figure 3C ) as compared to vehicle pre-treatment. In addition, we pre-treated MDA-MB-231 breast cancer cells, which also harbor a hyper-methylated CDH1 promoter, with ML327 followed by TRAIL and demonstrated increased percentage of cells in the Sub G 0 cell population as compared to vehicle pre-treated cells (Supplementary Figure 3D) . Taken together, these data demonstrate TRAIL sensitization after EMT reversal with ML327 is an E-cadherin-independent process.
cFLIP S modulates the apoptosis response in EMT
As E-cadherin de-repression was not required for ML327-induced TRAIL sensitization, we first assessed TRAIL receptor expression after ML327 treatment and found that ML327 had no effect on TRAIL-R1 and TRAIL-R2 expression (Supplementary Figure 4A) . TRAIL receptor N-linked and O-linked glycosylation has also been reported to modulate TRAIL sensitivity in carcinoma cells [26, 27] . However, ML327 treatment did not cause a shift in band migration on immunoblot, nor were any additional bands present, suggesting no alteration in TRAIL receptor glycosylation state by ML327 (Supplementary Figure 4A) .
We next performed a screen of several anti-apoptotic proteins including XIAP, cIAP1, cIAP2, Livin, Survivin, (A) Western blot analysis of siRNA-mediated knockdown of E-cadherin in SW620 cells demonstrating decreased E-cadherin levels without a reduction PARP cleavage relative to β-actin controls after 10 μM ML327 pre-treatment (24 hours) followed by 100 ng/mL TRAIL (4 hours). (B) Similar analysis in HCT-116 cells, which constitutively express E-cadherin. Approximately 50% knockdown was achieved with no blunting of PARP cleavage after 10 μM ML327 pre-treatment (24 hours) followed by 50 ng/mL TRAIL (4 hours). (C) Western blot of RKO cells pre-treated with 10 μM ML327 for 24 hours followed by 500 ng/mL TRAIL for 4 hours, in which ML327 is unable to de-repress E-cadherin, demonstrates increased PARP cleavage compared to vehicle pre-treatment. E-cadherin positive control utilized was the same concentration of protein lysate derived from HCT-116 cells. All blots are representative of n = 3 biologic replicates. and cFLIP and observed consistent reduction of cFLIP S protein levels after 24-hour ML327 treatment and no appreciable changes in the other proteins ( Figure 4A , Supplementary Figure 4B , and data not shown). While cFLIP S levels were consistently decreased by ML327 in SW620, HCT-116, A549 and RKO cells, cFLIP L modulation was inconsistent, with decreased levels in HCT-116 cells and unchanged levels in SW620 and RKO cells ( Figure 4A ). cFLIP L is thought to be pro-apoptotic at physiologic levels [11] [12] [13] whereas cFLIP S has been implicated as a master anti-apoptotic regulator [28] and has been shown to inhibit CD95, TNF-α, and TRAILinduced apoptosis [29] [30] [31] . We therefore focused our attention to cFLIP S .
To determine whether cFLIP S loss was sufficient to sensitize cancer cells to TRAIL, we performed siRNAmediated knockdown of cFLIP and demonstrated increased caspase 8 and PARP cleavage after treatment with TRAIL following loss of cFLIP expression ( Figure 4B ). Cells treated with control siRNA had less caspase 8 and PARP cleavage. The results of these experiments suggest that EMT reversal with ML327 leads to a reduction in cFLIP S protein and that reduction of cFLIP S is sufficient to sensitize cancer cells to TRAIL-induced apoptosis.
We next determined whether cFLIP S loss was necessary for ML327-induced TRAIL sensitization by overexpression of exogenous cFLIP S . We transiently transfected a constitutively active plasmid expressing cFLIP S in SW620, HCT-116, and RKO cells and showed that ML327 was unable to reduce cFLIP S protein with 24-hour treatment ( Figure 5A, Supplementary Figure 5A ). The cells were co-transfected with a GFP-expressing plasmid to assess transfection efficiency. At 48 hours after transfection, we achieved approximately 10-30% transfection efficiency, depending on cell line ( Figure 5B , Supplementary Figure 5B) . Transfected cells were then pre-treated with ML327 for 24 hours followed by TRAIL for an additional 4 hours. SW620 cells with cFLIP S overexpression had reduced caspase 8 and PARP cleavage ( Figure 5C ) after ML327 pre-treatment followed by TRAIL as compared to cells transfected with control plasmids. Similar results were seen in HCT-116 and RKO cells (Supplementary Figure 5B and 5C ). Taken together, these results suggest that cFLIP S protein loss is sufficient to sensitize cells to TRAIL-induced apoptosis and that cFLIP S protein loss is necessary for ML327-induced TRAIL sensitization.
cFLIP S mRNA expression is reduced with EMT reversal
Regulation of cFLIP S expression occurs at the transcriptional and post-transcriptional levels [26, 28, [32] [33] [34] [35] . In HCT-116, SW620, and RKO cells, cFLIP S mRNA levels were significantly reduced after 24-hour treatment with ML327 (HCT-116: p < 0.0001; SW620: p < 0.0001; RKO: p = 0.0005), mirroring the protein levels. (Figure 6A ). cFLIP L levels were reduced in HCT-116 cells but unchanged in SW620 and RKO cells (Supplementary Figure 6A) , also mirroring protein levels.
To determine whether the effect of ML327 on cFLIP S mRNA was due to differential expression of the major transcription factors known to modulate cFLIP expression, we queried our RNA sequencing data for FOXO3, E2F1, and MYC, NF-κB and TP53 expression [36] [37] [38] [39] [40] Figure 6B, Supplementary Tables 1-3) .
In HCT-116 cells, in which the reduction of cFLIP S mRNA was greatest, mRNA stability was unchanged with ML327 treatment ( Figure 6B ). In SW620 and RKO cells, in which the reduction of cFLIP S mRNA was not as robust, we tested for altered protein stability in response to ML327 and found none ( Figure 6C ). In addition, ML327 did not appear to alter global polysome profiles in SW620 and RKO cells (Supplementary Figure 6C) suggesting no differences in mRNA translation. Taken together, these results demonstrate that EMT reversal with ML327 causes a downregulation of cFLIP S mRNA expression.
DISCUSSION
Understanding the mechanism that drives EMT remains a major focus of cancer research. Small molecules that reverse EMT are useful tools as they enable manipulation of the EMT transcriptional program thereby allowing for subsequent analysis. We have previously described an isoxazole-based small molecule, ML327, that partially reverses TGF-β-induced EMT in immortalized mouse mammary epithelial cells resulting in a de-repression of E-cadherin expression [17] . In the current study, we performed RNA sequencing on 3 carcinoma cell lines after ML327 treatment and demonstrate a reversal of EMT via the downregulation of numerous EMT and stem-cell related genes. Ingenuity Pathway core expression analysis of RNA sequencing data performed on carcinoma cells treated with ML327 implicates "regulation of the EMT pathway" as a major canonical pathway. Furthermore, gene-expression profiles after ML327 treatment positively enrich with previously published gene sets associated with EMT reversal. We do note that the expression of major EMT transcription factors TWIST1, SNAI1, and ZEB1, is either unchanged or modestly upregulated by ML327 (Log2 FC < 1.5) in all 3 carcinoma cell lines (Supplementary Tables 1-3) , suggesting that the partial EMT reversal by ML327 is disconnected from the expression of these EMT regulators through an unknown mechanism. Our data suggest that the normal function of these transcription factors as transcriptional repressors may be abrogated by ML327 as we consistently observe CDH1 upregulation in the setting of increased SNAI1 and ZEB1 expression.
EMT is a major driver of apoptotic resistance in carcinomas [15] and we tested whether partial reversal with ML327 would re-sensitize carcinoma cells to TRAIL-induced apoptosis. Our data indicate that ML327 sensitizes carcinoma cells to TRAIL as evident by increases in PARP cleavage, caspase 8 cleavage, caspase 3/7 activation, Annexin V binding to PS residues, and Sub G 0 cell population after ML327 pre-treatment. A previous report suggested that E-cadherin expression is necessary for TRAIL sensitivity [16] ; however, our data support that the effect of TRAIL sensitization by ML327 is independent of E-cadherin expression. Although E-cadherin loss is considered a hallmark of EMT [3] , there are many other phenotypic manifestations of this process and our data suggest that E-cadherin may be a secondary factor in EMT-associated resistance to apoptosis.
Instead of E-cadherin, our data implicate cFLIP S as a critical regulator of EMT-associated resistance to apoptosis. Our results show that ML327 treatment causes downregulation of cFLIP S mRNA expression with subsequent protein reduction. cFLIP S knockdown by small interfering RNA was sufficient to sensitize carcinoma cells to TRAIL. While cFLIP L was also knocked down, evidence suggests cFLIP L is pro-apoptotic at physiologic levels [11] [12] [13] making it an unlikely regulator of ML327-induced TRAIL sensitization. Exogenous overexpression of cFLIP S inhibited the ability of ML327 to sensitize carcinoma cells to TRAIL. Complete rescue was not achieved, however, and this was likely due to low transient transfection efficiencies despite multiple attempted transfection modalities. Taken together, our findings suggest that cFLIP S is a critical modulator of EMT-associated resistance to apoptosis. It will be of interest to determine whether the EMT link with cFLIP S also participates in the mechanism of apoptosis resistance in response to other cancer therapeutic agents.
While we have shown that ML327 sensitizes carcinoma cells to TRAIL via partial EMT reversal and downregulation of cFLIP S mRNA expression, a complete understanding of the direct mechanism has not yet been elucidated. Interestingly, ML327 only consistently affects cFLIP S mRNA levels and not cFLIP L levels. With no appreciable difference in mRNA stability and no global difference in polysome profiles, it is possible that ML327 is modulating alternative splicing of cFLIP pre-mRNA. There are 15 known splice variants of cFLIP and while 3 are translated into proteins, the remaining 12 are targeted for degradation via the nonsense mediated decay pathway. It has been recently shown that several post-translational (B) cFLIP S mRNA stability was assessed by pre-treating HCT-116 cells with ML327 for 2 hours followed by the addition of 5 µg/mL Actinomycin D. Cells were lysed at indicated time points and RT-qPCR was performed as above. A one phase, exponential decay analysis using a non-linear, least squares regression model was performed with no difference in cFLIP S mRNA stability (p = 0.093) as determined by the extra sum-of-squares F test. RT-qPCR using MYC primers was performed as a positive control for actinomycin D activity. Data represented as mean ± SEM. Each data point represents a mean of n = 3 biologic replicates. (C) cFLIP S protein half-life was assessed by pre-treating cells with ML327 for 6 hours followed by the addition of cycloheximide. Cells were lysed at indicated time points and western blot was performed. ML327 did not reduce cFLIP S protein half-life. Figure is representative of n = 3 biologic replicates. www.impactjournals.com/oncotarget modifications on histones regulate alternative splicing of mRNA by modulating the recruitment of various splicing factors [41] . Unpublished data from our lab suggests that ML327 treatment causes increased H3K9 acetylation, H3K4 tri-methylation, and H3K27 acetylation on a global scale lending to the possibility that ML327 is indirectly altering pre-mRNA splicing of cFLIP through these histone modifications. Further study into this mechanism is warranted.
The direct intracellular target of ML327 has yet to be identified. Radioisotope, biotin, and iodine labeling of ML327 have all been attempted but these modifications have reduced the biological activity of ML327 in vitro suggesting that they reduce target affinity (data not shown). EMT reversal has been reported with other experimental therapeutics including histone deacetylase inhibitors (HDACi) and bromodomain inhibitors. Indeed, Trichostatin A, a non-specific HDACi, has been shown to derepress E-cadherin in carcinoma cells [42] . These compounds have also been shown to downregulate cFLIP, albeit by a reduction in protein stability [43, 44] . We have tested whether ML327 inhibits class I, II, III, and IV HDACs and found it to have no direct inhibitory effect on histone deacetylase activity [42] . Efforts are ongoing to determine the direct mechanism of action for ML327.
Despite an elusive intracellular target protein, ML327 remains an intriguing small molecule with therapeutic potential. In vivo studies have demonstrated that ML327 can be delivered intraperitoneally in a mouse model with excellent drug metabolism and pharmacokinetics (DMPK) profiles [18] . Further studies with ML327 in pre-clinical animal models are ongoing.
In conclusion, EMT is a mechanism linked to acquisition of resistance to apoptosis-inducing agents in cancer cells. This study demonstrates EMT reversal with ML327 sensitizes carcinoma cells to TRAIL-induced apoptosis and implicates cFLIP S as the critical link between EMT and apoptosis resistance. While the exact mechanism of cFLIP S downregulation by ML327 is still unknown, the therapeutic implications of small molecules that can reverse EMT warrant further investigation as they may provide improved understanding of therapeutic resistance in cancer along with potentially novel therapeutic approaches.
MATERIALS AND METHODS
Reagents
TRAIL was purchased from Bio Vision (#4354-50, San Francisco, CA) and was also graciously provided by Dr. Avi Ashkenazi (Genetech, San Francisco, CA). Actinomycin D was purchased from EMD Millipore (Billerica, MA). Cycloheximide was purchased from Sigma-Aldrich (St. Louis, MO).
Cell culture
The HCT-116 parental cell line (HD-PAR-007) was obtained from Horizon Discovery Group (Cambridge, United Kingdom) and the SW620 (CCL-227), RKO (CRL-2577), A549 (CCL-185) and MDA-MB-231 (HTB-26) cell lines were obtained from American Type Culture Collection (ATCC) (Manassas, VA). Cells were maintained in humidified incubator at 37 o C and 5% CO 2 . All cell lines were routinely cultured in RPMI 1640 media with L-glutamine (Thermo Fisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Norcross, GA), and 50 µg/mL of penicillin/ streptomycin (Corning, Manassas, VA). Cell lines were authenticated via short tandem repeat (STR) profiling by Genetica Cell Line Testing (Burlington, NC) on a yearly basis, most recently in September, 2016. All cell lines were routinely tested for mycoplasma contamination using the MycoSensor PCR Assay Kit -#302108 -(Agilent Technologies, Santa Clara, CA) and were negative.
RNA isolation and quantitative RT-PCR
RNA was extracted from cells using the RNeasy kits (Qiagen, Valencia, CA) per manufacturer's instructions. RNA concentrations were measured using a NanoDrop spectrophotometer (Thermo Scientific, Wilmington, DE). cDNA was reverse transcribed using iScript ™ Reverse Transcription Supermix for RT-qPCR (Bio Rad, Hercules, CA) per manufacturer's instructions. Quantitative RT-PCR was performed using a LightCycler ® 480 II instrument (Roche Biologicals, Basel, Switzerland). PCR instrumentation and reagents were obtained through Roche Biologicals (Basel, Switzerland). cFLIP S primers were designed as described in Ewald et al [45] and RTqPCR was performed using the iQ SYBR ® Green Supermix (Bio Rad, Hercules, CA). cFLIP S Forward Primer Sequence: 5ʹ -GCAGCAATCCAAAAGAGTCTCA -3ʹ. cFLIP S Reverse Primer Sequence: 5ʹ -ATTTCCAAG AATTTTCAGATCAGGA-3ʹ. cFLIP L and cMYC primers and corresponding probe were designed using the Universal ProbeLibrary Assay Design Center (Roche Biologicals) and RT-qPCR was performed using the monocolor hydrolysis probe/UPL probe system (Roche Biologicals) . cFLIP L Forward Primer Sequence: 5ʹ -GCT CACCATCCCTGTACCTG -3ʹ. cFLIP L Reverse Primer Sequence: 5ʹ -CAGGAGTGGGCGTTTTCTT -3ʹ. Associated probe for the cFLIP L primers was UPL # 14. MYC Forward Primer Sequence: 5ʹ -GCTGCTTAG ACGCTGGATTT -3ʹ. MYC Reverse Primer Sequence: 5ʹ -TAACGTTGAGGGGCATCG -3ʹ. Associated probe for the cMYC primers was UPL # 66.
RNA sequencing
RNA from HCT-116, SW620, and A549 cancer cells (n = 3 per group) treated with either DMSO or ML327 for 24 hours was collected using RNeasy kits. Processing of RNA using a TruSeq Stranded mRNA sample prep kit was conducted according to the manufacturer's instructions (Illumina, San Diego, CA). Approximately 27-36 million 50 base pair single-end reads were generated, per sample. We mapped the reads to the human genome hg19 using TopHat-2.0.10 [46] . 96% of the reads were mapped to the genome. Then, following the method of Anders et al [47] , we counted the number of reads that fell into annotated genes by samtools-0.1.19 [48] and HTSeq-0.5.4p5 [49] . Finally, we performed count-based differential expression analysis using edgeR_3.4.2 [50] , which implements general differential analyses based on the negative binomial model.
Gene set enrichment analysis and ingenuity pathway analysis
Gene set enrichment analysis software was obtained through the Broad Institute (http://software.broadinstitute. org/gsea/index.jsp) and analyses were performed according to Broad Institute guidelines [51, 52] . Gene sets were obtained from the Molecular Signatures Database (MSigDB) 4.0 (http://www.broadinstitute.org/gsea/msigdb/). Ingenuity Pathway Analysis software was obtained from QIAGEN Bioinformatics (QIAGEN, Redwood City, CA). Differentially expressed gene lists were analyzed according to software specifications. Canonical pathway analysis was performed as described in Haddad et al. [53] .
Protein expression
Whole cells were lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% Na deoxycholate, 0.1% SDS, 50 mM Tris-Cl, pH = 8.0) supplemented with a protease inhibitor cocktail consisting of 1 μg/mL aprotinin, 1 μg/mL leupeptin, 3 μg/mL Pepstatin, 1 mM NaVO3, 1 mM NaF, 0.5 μM DTT (Sigma Chemical, St. Louis, MO). Protein lysates were separated on 10% SDS-polyacrylamide gels. Antibodies used were as follows: cFLIP human (Enzo Life Sciences #ALX-804-961-0100, Farmingdale, NY) [16] ; cFLIP mouse (Abcam #ab8421, Cambridge, MA); total PARP, cleaved PARP, caspase 8, TRAIL-R2, p53, and NFKB1 (Cell Signaling Technology #9532, #5625, #9746, #8074, #2524, and #13586 Danvers, MA); TRAIL-R1 (Thermo Scientific, #32A1380); E-cadherin (BD Transduction Laboratories #610182, Franklin Lakes, NJ); β-actin (Sigma Chemical #A5441, St. Louis, MO); GAPDH (Life Technologies #AM4300, Carlsbad, CA); anti-mouse and anti-rabbit secondary antibodies (Santa Cruz Biotechnology #sc2005 and #sc-2004, Dallas, TX). Chemiluminescent western blot analyses were performed using ECL detection (EMD Millipore, Darmstadt, Germany).
Cell cycle analysis
Cells were trypsinized and fixed in 70% ethanol overnight at 4°C. Fixed cells were re-suspended in phosphate buffered saline (PBS) and stained with a propidium iodide (PI) cocktail consisting of PI, ribonuclease, and PBS. FACS cell-cycle analysis was performed after 30- 
Gene knockdown
siRNA knockdown was performed using pooled siRNA oligonucleotides obtained from Dharmacon ™ (Lafayette, CO). Sequences are as follows: si-CFLAR 1: 5ʹ GUGCCGGGAUGUUGCUAUA 3ʹ si-CFLAR 2: 5ʹ CAA GCAGUCUGUUCAAGGA 3ʹ si-CFLAR 3: 5ʹ CAUGGU AUAUCCCAGAUUC 3ʹ si-CFLAR 4: 5ʹ CCUAGGAAU CUGCCUGAUA 3ʹ si-CDH1 1: 5ʹ GGCCUGAAGUGA CUCGUAA 3ʹ si-CDH1 2: 5ʹ GAGAACGCAUUGCCAC AUA 3ʹ si-CDH1 3: 5' GGGACAACGUUUAUUACUA 3ʹ si-CDH1 4: 5ʹGACAAUGGUUCUCCAGUUG 3ʹ Cells were transfected using Dharmacon ™ DharmaFECT ™ transfection reagent according to manufacturer's guidelines. Non-targeting siRNA, also obtained from Dharmacon ™ were used as controls.
Gene overexpression
cFLIP short (Transcript Variant 3) plasmid was purchased from OriGene (Rockville, MD), amplified in E. coli, and purified using the QIAGEN Maxi Kit (Qiagen, Valencia, CA) per manufacturer's instructions. DNA was sequenced (GeneWiz, South Plainfield, NJ) using sequencing primers purchased from OriGene and sequences were validated using NCBI Basic Local Alignment Search Tool (https://blast.ncbi.nlm.nih.gov/Blast.cgi). Cells were transfected with plasmid DNA using Effectene transfection reagent (Qiagen) per manufacturer's instructions. Transfection efficiency was determined by co-transfecting a GFP expressing plasmid and fluorescent microscopic analysis.
Polysome profiling Buffers
Polysome lysis buffer was prepared as follows: 10 mM Tris-Cl, pH:7.5; 100 mM NaCl; 30 mM MgCl 2 ; 200 µg/mL Heparin, 100 µg/mL Cycloheximide; 0.5% Triton X-100. Polysome gradient buffer (10×) was prepared as follows: 500 mM Tris-Cl, pH:7; 500 mM NH 4 Cl, 120 mM MgCl 2 . 50% and 10% sucrose solutions were prepared from appropriate volumes of 70% stock sucrose solution and 10× gradient buffer and cycloheximide was added at a 50 µg/mL concentration.
Analysis
Cells were treated in-vitro with ML327 (or vehicle control) for 24 hours and then cycloheximide (100 µg/mL) was added for 5 minutes. Cells were then lysed in polysome lysis buffer. Lysates were centrifuged at 1000g for 3 minutes at 4°C. OD260 of the cleared lysate was measured on the NanoDrop (Thermo Scientific, Wilmington, DE). 15 OD units of lysate were layered onto 13 mL 50%-10% sucrose gradients. Gradients were then centrifuged using a Beckman SW-41 rotor at 222,000 g for 3 hours at 4 o C. Polysome profiling was then performed as previously described by Link et al [54] .
Statistical analysis
All in vitro experiments were performed at least three separate times (except for caspase 3/7 and Annexin V luminescence experiments) to ensure validity of results. For all in vitro experiments, means were compared with the student t-test, one-way ANOVA with Tukey correction for multiple comparisons (≥ 3 comparisons), or two-way ANOVA with Tukey correction for multiple comparisons (≥ 3 comparisons).
Abbreviations
EMT: epithelial to mesenchymal transition; cFLIP: cellular FLICE-like Inhibitory Protein, TRAIL: tumor necrosis factor-related apoptosis inducing ligand; PARP: poly ADP-ribose polymerase; PS: phosphatidylserine; HDAC: histone deacetylase; DMPK: drug metabolism and pharmacokinetics. 
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